...合并冠心病是临床上常见且特殊的患者群,对该类患者如何正确地进行抗栓治疗是临床亟需解决的棘手问题。非维生素K拮抗剂口服抗凝药(NOAC)是近年来新出现的口服抗凝药,在房颤卒中预防中已取代华法林成为首选口服抗凝药物,但其在房颤合并冠心病患者中的疗效和安全性仍...
基于52个网页-相关网页
《国际循环》:关于口服抗凝药治疗,我们如何保持安全性和有效性之间的平衡?
International Circulation: In oral anticoagulant therapy, how can we make the balance between safety and efficacy?
此外,尽管口服抗凝药的实验监测也许并无必要,但还需开发这类药物的解毒剂并对其效果加以检测。
Moreover, although lab monitoring with oral anticoagulant may not be necessary, antidotes of such compounds still need to be developed and tested for their efficacy.
这项研究例证了新型特异性口服抗凝药可改善当前的抗血栓治疗方法,并有有着较为安全的出血特性。
This study exemplifies that novel, specific oral anticoagulants may improve the current antithrombotic strategies while having a safer bleeding profile.
应用推荐